Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$70.75−0.31 (-0.44%)
Close on Nov 18, 2026Market cap $474.89MP/E –Yield –
Monopar Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Monopar Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$22.12M. For fiscal 2025 it was -$16.70M. The highest annual figure on record is -$1.19M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.70M | – |
| FY2024 | Dec 31, 2024 | -$16.16M | – |
| FY2023 | Dec 31, 2023 | -$8.83M | – |
| FY2022 | Dec 31, 2022 | -$10.54M | – |
| FY2021 | Dec 31, 2021 | -$9.13M | – |
| FY2020 | Dec 31, 2020 | -$6.51M | – |
| FY2019 | Dec 31, 2019 | -$4.32M | – |
| FY2018 | Dec 31, 2018 | -$3.33M | – |
| FY2017 | Dec 31, 2017 | -$16.60M | – |
| FY2016 | Dec 31, 2016 | -$1.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.22M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.09M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.65M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$759.45K | – |
| Q2 FY2019 | Jun 30, 2019 | -$932.11K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.41M | – |
| Q4 FY2018 | Dec 31, 2018 | -$926.36K | – |
| Q3 FY2018 | Sep 30, 2018 | -$667.53K | – |
| Q2 FY2018 | Jun 30, 2018 | -$667.53K | – |
| Q1 FY2018 | Mar 31, 2018 | -$897.26K | – |
| Q4 FY2017 | Dec 31, 2017 | -$736.80K | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -$594.96K | – |
| Q1 FY2017 | Mar 31, 2017 | -$373.84K | – |
See a number that looks wrong?